Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Journal of Clinical Oncology · 20.11.2025 · 43 (33) · 3573-3577
DOI: 10.1200/jco-25-00668 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2025. Verfasst von Sattva S Neelapu und 22 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Antigens, CD19, Lymphoma, Non-Hodgkin, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Here, we report updated clinical outcomes from ZUMA-5 in 159 enrolled patients with R/R indolent non-Hodgkin lymphoma (iNHL; 127 with FL and 31 with marginal zone lymphoma) after a median follow-up of 64.6 months. Patients underwent leukapheresis and received lymphodepleting chemotherapy and axi-cel (2 × 10 6 CAR T cells/kg). The overall response rate was 90% (75% complete response rate). The median duration of response was 60.4 months, and the median progression-free survival (PFS) was 62.2 months; median time to next treatment and overall survival were not reached (NR). At data cutoff, 55% of patients were alive without requiring subsequent anticancer therapy. Median lymphoma-specific PFS in patients with FL was NR; 34% had progression or death due to lymphoma or study treatment. Notably, after 30 months postinfusion, progression or lymphoma-related deaths were rare. Late-onset toxicities were infrequent and largely unrelated to axi-cel. Durable response and prolonged survival in FL were associated with robust early CAR T-cell expansion and naïve product phenotype. These findings confirm sustained responses and manageable safety with axi-cel in the long term among patients with R/R iNHL and its potential as a curative therapy in FL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The University of Texas MD Anderson Cancer Center, Houston, TX.
- Moffitt Cancer Center, Tampa, FL.
- UPMC Hillman Cancer Center, Pittsburgh, PA.
- The Ohio State University Comprehensive Cancer Center, Columbus, OH.
- Banner MD Anderson Cancer Center, Gilbert, AZ.
- Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
ORCID-Profile: Sattva S Neelapu, Julio C Chavez, Narendranath Epperla, Matthew L Ulrickson, Emmanuel Bachy, Pashna N Munshi, Carla Casulo, Ran Reshef, Olalekan O Oluwole, Ibrahim Yakoub-Agha, Rhine R Shen, Caron A Jacobson
Zitieren
APA
Neelapu, S. S., Chavez, J. C., Sehgal, A. R., Epperla, N., Ulrickson, M. L., Bachy, E., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., Reshef, R., Leslie, L. A., Oluwole, O. O., Yakoub-Agha, I., Khanal, R., Rosenblatt, J. D., Wulff, J., Shen, R. R., Zhang, W., …, & Jacobson, C. A. (2025). Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Journal of Clinical Oncology, 43(33), 3573-3577. https://doi.org/10.1200/jco-25-00668
Vancouver
Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson ML, Bachy E, et al. Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Journal of Clinical Oncology. 2025;43(33):3573-3577. doi:10.1200/jco-25-00668
BibTeX
@article{Neelapu2025,
author = {Neelapu, Sattva S and Chavez, Julio C and Sehgal, Alison R and Epperla, Narendranath and Ulrickson, Matthew L and Bachy, Emmanuel and Munshi, Pashna N and Casulo, Carla and Maloney, David G and de Vos, Sven and Reshef, Ran and Leslie, Lori A and Oluwole, Olalekan O and Yakoub-Agha, Ibrahim and Khanal, Rashmi and Rosenblatt, Joseph D and Wulff, Jacob and Shen, Rhine R and Zhang, Wangshu and Poddar, Soumya and Miao, Harry and Nikolajeva, Olga and Jacobson, Caron A},
title = {Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {33},
pages = {3573--3577},
doi = {10.1200/jco-25-00668}
}
EUVIMED